Biologists at UC San Diego have discovered a chemical that offers a completely new and promising direction for the development of drugs to treat metabolic disorders such as type 2 diabetes.
Researchers at the UC San Diego School of Medicine are evaluating a new social media tool called Wellaho to treat patients with type I and II diabetes. The clinical trial will study whether the use of social networking can improve patient-physician interactions and the patient’s overall health and wellbeing.
In a paper published in the July 11 online issue of Science Translational Medicine, researchers at the University of California, San Diego School of Medicine have identified two key regulatory proteins critical to clearing away misfolded proteins that accumulate and cause the progressive, deadly neurodegeneration of Huntington’s disease (HD).
Researchers at the University of California, San Diego School of Medicine say they have identified a set of laboratory-based biomarkers that can be useful for understanding brain-based abnormalities in schizophrenia. The measurements, known as endophenotypes, could ultimately be a boon to clinicians who sometimes struggle to recognize and treat the complex and confounding mental disorder.
Fudan University in Shanghai, China is partnering with the University of California to establish a Fudan-UC center to foster academic exchange and collaborative research on China. The center, a first-of-its-kind internationalization initiative made by a major Chinese university, will be located on the campus of the University of California, San Diego, hosted by the campus’ School of International Relations and Pacific Studies (IR/PS).
The biological mechanism of sunburn – the reddish, painful, protective immune response from ultraviolet (UV) radiation – is a consequence of RNA damage to skin cells, report researchers at the University of California, San Diego School of Medicine and elsewhere in the July 8, 2012 Advance Online Publication of Nature Medicine.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
